New drug mix would simplify HIV therapy

Article Abstract:

While the current AIDS "drug cocktail" treatment program for HIV-infected patients requires taking from 10 to 20 pills a day, two companies have introduced new products to greatly reduce the number of pills per day required for effective treatment of HIV. Dupont Co. has developed a new, still unapproved drug called Sustiva that can be taken as one pill once a day. Glaxo Wellcome PLC has developed a new twice a day pill that combines both AZT and 3TC. The Dupont once-a-day pill can be taken with the Glaxo twice-a-day pill to create what researchers say is a combination that can counter HIV as well as or better than the current cocktail mix.

Comment:

Dupont introduces a new anti-HIV drug that need be taken only once a day

Product development, Antiinfective Preparations NEC, Anti-infective agents, Glaxo Wellcome PLC, E.I. du Pont de Nemours and Co.

---

Johnson & Johnson drug may pose risks

Article Abstract:

The Food and Drug Administration (FDA) regulators warned that a popular heartburn drug called Propulsid, manufactured by Johnson & Johnson, may cause potentially deadly heart-rhythm problems when taken in combination with other medications. The FDA recommended that the drug be taken only after all other options have failed, and included a list of other drugs that should not be taken with Propulsid. Based in New Brunswick, NJ, Johnson & Johnson will feel the impact of the FDA warning because Propulsid is one of the company's top-selling drugs, with sales of over $1 billion in 1997.

Comment:

FDA warns popular heartburn drug, Propulsid by Johnson & Johnson, may cause potentially deadly heart-rhythm problems

Government regulation (cont), Antacid Preparations, Johnson & Johnson, Antacids

---

Genentech earnings jump 70% on launch of lymphoma drug

Article Abstract:

Genentech Inc. announced that its net income for the second-quarter of 1998 improved 70% to $40.4 million. The improved net income was a reflection of the launch of Genentech's new Rituxan lymphoma drug. The company posted $23.8 million in quarterly earnings in 1997. Its revenue increased 15% for the quarter to $268 million. Rixutan sales fell slightly in the quarter to $34.8 million.

Comment:

Announced that its net income for the second-quarter of 1998 improved 70% to $40.4 million

Sales, profits & dividends, Biological Product (except Diagnostic) Manufacturing, Biological Products, Genentech Inc.

Similar abstracts:

• Abstracts: Accruals quality and internal control over financial reporting. Measuring reporting conservatism
• Abstracts: Computing returns the feel-good way. A new language may ease Web use. You are not alone: trial by CD-ROM
• Abstracts: Tough times in the video trade. Outsourced employment agency has a big job ahead of it. Insurer goes directly for the good risks
• Abstracts: GST promises to keep the industry on its toes. CEOs give coalition a qualified tick
• Abstracts: GM recalls nearly a million cars, citing a problem with air bags

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.